Full-Time

Materials Coordinator 1/2

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$50k - $58k/yr

Carlsbad, CA, USA

In Person

Category
Operations & Logistics (2)
,
Requirements
  • Minimum high school diploma, or equivalent
  • Ability to read, understand, and carry out Standard Operating Procedures (SOP’s), Work Instructions and other Quality Process Documentation in English
  • Proven ability to provide excellent written and oral communication skills
  • Knowledge of standard concepts, practices and procedures within the manufacturing and biologic environment preferred
  • Microsoft Office experience
  • Working knowledge of ERP system preferred
  • FLSA: Non-Exempt
Responsibilities
  • Support and work within the Code of Federal Regulations Title 21, Quality Management System, Standard Operation Procedures (SOP’s), Work Instructions, comply with all documentation needs, and practices.
  • Perform timely and accurate data entry in Enterprise Resource Planning (ERP) for material transactions.
  • Perform receipt of incoming materials. Check materials received against specifications, vendor shipping documents and purchase orders for accuracy.
  • Accurately maintain all receiving documentation to comply with internal procedures and or SOPs.
  • Follow best practices related to the systems and process that support material inventory, purchasing, and material control. Provide recommendations and assist with implementation of improvements.
  • Work with Purchasing and Accounts Payable to resolve any supplier invoice issues or discrepancies.
  • Coordinate with Quality Assurance and Quality Control personnel, ensuring timely testing and release of materials.
  • Conduct cycle counts and wall-to-wall counts as needed.
  • Pick and stage materials for manufacturing and laboratory support.
  • Support accurate client billing and raw material traceability through timely processing of return to stock items.
  • Inspect stock for damage/product integrity. Maintain organization of work areas through 6S (sort, set, standardize, shine, sustain, safety).
  • Interact with Manufacturing and laboratory departments to reconcile inventory variances.
  • Perform packaging and shipping of materials and samples to customers and/or testing facilities. Monitor shipments and update of any potential delays.
  • Manage effective relationships with suppliers as well as internal and external clients.
  • Successfully adapt to changing priorities in a high operating tempo.
  • Operate heavy equipment and vehicles to move materials. (Valid Class C license for driving company van or truck)
  • Operate to the highest ethical and moral standards.
  • Comply with Abzena's policies and procedures.
  • Communicate effectively with regulators, clients, supervisors, colleagues, and staff.
  • Participate effectively as a team player in all aspects of Abzena's business.
  • Adhere to quality standards set by regulations and Abzena policies, procedures, and mission.
  • Perform other duties as assigned. (Cleaning, labeling, printing, etc.)
Desired Qualifications
  • Preferred minimum two (2) years’ experience in materials management.
  • Preferred minimum one (1) year experience working in Pharmaceutical environment.
  • Knowledge of standard concepts, practices and procedures within the manufacturing and biologic environment preferred
  • Working knowledge of ERP system preferred

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Abzena who can refer or advise you

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.